×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Cell: Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis
cell
2,270 words
KG: Als
2026-03-27
kind:cell-type
section:cell-types
state:published
topic:als
topic:neurodegeneration
Contents
Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis
🧫
Cell Type Info
Cell Type
Als
Associated Diseases
Aging
,
Alzheimer
,
Amyotrophic Lateral Sclerosis
,
Anxiety
,
Ataxia
Linked Hypotheses
297 hypotheses
Knowledge Graph
Related Hypotheses (30)
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
Score: 0.48
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.66
CYP46A1 Overexpression Gene Therapy
Score: 0.63
APOE-Dependent Autophagy Restoration
Score: 0.61
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate
Score: 0.61
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
Adenosine-Astrocyte Metabolic Reset
Score: 0.56
Circadian Clock-Autophagy Synchronization
Score: 0.55
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Temporal Decoupling via Circadian Clock Reset
Score: 0.52
Noradrenergic-Tau Propagation Blockade
Score: 0.51
Aquaporin-4 Polarization Rescue
Score: 0.51
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
Stress Granule Phase Separation Modulators
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Show 25 more
Related Analyses (30)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Show 25 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
MAP6 depletion effects on neuronal development in primary cu
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Mouse Cdk5, p35, and p39 mutations in neuronal migration
validation · proposed · Score: 0.80
Reelin pathway defects in human type 2 lissencephaly
exploratory · proposed · Score: 0.70
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
Prion Strain Diversity and Selective Vulnerability
clinical · proposed · Score: 0.40
Show 25 more
See Also (2)
ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates
A2M Gene
gene · KG edge: interacts_with
Knowledge Graph (12 edges)
Als
associated_with
Synaptic Plasticity
Als
associated_with
Ms
Als
associated_with
Cardiac
Als
associated_with
Parkinson
Als
expressed_in
Dna Methylation
Als
therapeutic_target
Wnt
Als
activates
Glycolysis
Als
interacts_with
Autophagy
Als
inhibits
Akt
Als
inhibits
Pi3K